What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study

被引:9
|
作者
Shim, Geumsook [1 ]
Park, Hye Youn [1 ]
Jang, Joon Hwan [1 ]
Kim, Euitae [1 ]
Park, Hye Yoon [1 ]
Hwang, Jae Yeon [1 ,2 ]
Kim, Sung Nyun [1 ]
Jang, Go-Eun [3 ]
Kwon, Jun Soo [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea
[2] Seoul Natl Univ, Brain & Cognit Sci WCU Program, Coll Nat Sci, Seoul 110744, South Korea
[3] SNU MRC, Clin Cognit Neurosci Ctr, Neurosci Inst, Seoul, South Korea
关键词
escitalopram; high dose; obsessive-compulsive disorder; selective serotonin reuptake inhibitors; SEROTONIN REUPTAKE INHIBITORS; POSITRON-EMISSION-TOMOGRAPHY; SOCIAL ANXIETY DISORDER; DOUBLE-BLIND; PREFRONTAL CORTEX; 20; MG; PLACEBO; PHARMACOTHERAPY; DOPAMINE; TRANSPORTER;
D O I
10.1097/YIC.0b013e32834a5c09
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of <= 20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting. We reviewed the medical records of all patients with obsessive-compulsive disorder (n = 246) who had taken ESC between May 2006 and September 2009, and assigned Clinical Global Impression (CGI) scores, retrospectively. Of the total sample, 24.4, 38.2, and 37.4% patients received very high, high, and standard doses of ESC, and the mean daily maximum doses of ESC were 57.3 +/- 12. mg, 33.9 +/- 5.4 mg, and 13.4 +/- 5.8 mg, respectively. The CGI-Severity scores in each group decreased significantly after treatment with ESC, as evidenced by response rates (i.e. CGI-Improvement scores of 1 or 2) of 46.3, 43.2, and 26.2%, respectively. Although some adverse events increased in a dose-dependent manner, most could be managed with an ESC dose adjustment. These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Int Clin Psychopharmacol 26:284-290 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [1] Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study
    Stryjer, Rafael
    Dambinsky, Yael
    Timinsky, Igor
    Green, Tamar
    Kotler, Moshe
    Weizman, Abraham
    Spivak, Baruch
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (02) : 96 - 98
  • [2] Obsessive-compulsive disorder:: An open-label pilot trial of escitalopram
    Almeida, Amanda Galvao-de
    Quarantini, Lucas C.
    Gois, Cristianne R.
    Santos-Jesus, Rogerio
    Miranda-Scippa, Angela M. A.
    de Oliveira, Irismar R.
    Prado, Helena da Silva
    Leckman, James F.
    Rosario, Maria C.
    CNS SPECTRUMS, 2007, 12 (07) : 519 - 524
  • [3] A naturalistic, open-label study of very high-dose (&gt;40mg/day) escitalopram for the treatment of obsessive-compulsive disorder
    Shim, G.
    Park, H. Y.
    Jang, J. H.
    Kim, E.
    Kwon, J. S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 201 - 201
  • [4] Open-Label Study of Duloxetine for the Treatment of Obsessive-Compulsive Disorder
    Dougherty, Darin D.
    Corse, Andrew K.
    Chou, Tina
    Duffy, Amanda
    Arulpragasam, Amanda R.
    Deckersbach, Thilo
    Jenike, Michael A.
    Keuthen, Nancy J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (02): : 1 - 4
  • [5] Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder
    Dougherty, Darin D.
    Jameson, Mariko
    Deckersbach, Thilo
    Loh, Rebecca
    Thompson-Hollands, Johanna
    Jenike, Michael
    Keuthen, Nancy J.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (06) : 306 - 311
  • [6] Venlafaxine open-label treatment of patients with obsessive-compulsive disorder
    Sevincok, L
    Uygur, B
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2002, 36 (06): : 817 - 817
  • [7] The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study
    Rubin-Kahana, Dafna Sara
    Shelef, Assaf
    Weizman, Abraham
    Gothelf, Doron
    Timinski, Igor
    Spivak, Baruch
    Stryjer, Rafael
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (04) : 179 - 183
  • [8] High dose escitalopram for the treatment of obsessive-compulsive disorder
    Barak, Y.
    Rabinowitz, I.
    Baruch, Y.
    JOURNAL OF AFFECTIVE DISORDERS, 2008, 107 : S82 - S82
  • [9] Bupropion for patients with obsessive-compulsive disorder: An open-label, fixed-dose study
    Vulink, NCC
    Denys, D
    Westenberg, HGM
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (02) : 228 - 230
  • [10] Naltrexone in Obsessive-Compulsive Disorder: an Open-Label Trial
    Hamidi, Aram
    Jahanguiri, Bijan
    Esfahani, Mehdi Nasr
    Dadfar, Mahbuobeh
    IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES, 2007, 1 (01) : 16 - 21